<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'><collection><source>PubTator</source><date></date><key>BioC.key</key><document><id>4181680</id><passage><infon key="name_3">surname:Xu;given-names:Jingyao</infon><infon key="name_2">surname:Welch;given-names:Crystal</infon><infon key="name_1">surname:Desai;given-names:Akshata</infon><infon key="name_0">surname:Aysola;given-names:Kartik</infon><infon key="year">2014</infon><infon key="article-id_doi">10.4172/2161-1041.S2-001</infon><infon key="type">front</infon><infon key="section_type">TITLE</infon><infon key="article-id_manuscript">NIHMS631404</infon><infon key="issue">Suppl 2</infon><infon key="elocation-id">001</infon><infon key="volume">2013</infon><infon key="license">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</infon><infon key="name_10">surname:Piyathilake;given-names:Chandrika J</infon><infon key="name_11">surname:Reddy;given-names:Shyam P</infon><infon key="name_12">surname:Rao;given-names:Veena N</infon><infon key="kwd">TNBC BRCA1 CISPLATIN EGFR PARP Hedgehog NOTCH BCL-2 UBC9 WNT/B-CATENIN</infon><infon key="name_9">surname:Beech;given-names:Derrick J</infon><infon key="name_8">surname:Okoli;given-names:Joel</infon><infon key="name_7">surname:Owens;given-names:Charlotte</infon><infon key="name_6">surname:Matthews;given-names:Roland</infon><infon key="name_5">surname:Reddy;given-names:Vaishali</infon><infon key="name_4">surname:Qin;given-names:Yunlong</infon><infon key="article-id_pmc">4181680</infon><infon key="article-id_pmid">25285241</infon><offset>0</offset><text>Triple Negative Breast Cancer - An Overview</text><annotation id="23857"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="0" length="29" /><text>Triple Negative Breast Cancer</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>46</offset><text>Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic women who carry a mutation in the BRCA1 gene. TNBC is characterized by a distinct molecular profile, aggressive nature and lack of targeted therapies. The purpose of this article is to review the current and future novel signalling pathways as therapeutic approaches to TNBC. Recent Identification of a new BRCA1 trafficking pathway holds promise in the future for the development of targeted therapies for TNBC.</text><annotation id="23858"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="154" length="17" /><text>estrogen receptor</text></annotation><annotation id="23859"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="173" length="2" /><text>ER</text></annotation><annotation id="23860"><infon key="identifier">5241</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">713</infon><location offset="187" length="21" /><text>progesterone receptor</text></annotation><annotation id="23861"><infon key="identifier">5241</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">713</infon><location offset="210" length="2" /><text>PR</text></annotation><annotation id="23862"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="233" length="34" /><text>epidermal growth factor receptor 2</text></annotation><annotation id="23863"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="269" length="4" /><text>HER2</text></annotation><annotation id="23864"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="377" length="5" /><text>BRCA1</text></annotation><annotation id="23865"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="650" length="5" /><text>BRCA1</text></annotation><annotation id="23866"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="613" length="4" /><text>TNBC</text></annotation><annotation id="23867"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="324" length="5" /><text>women</text></annotation><annotation id="23868"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="750" length="4" /><text>TNBC</text></annotation><annotation id="23869"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="77" length="4" /><text>TNBC</text></annotation><annotation id="23870"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="46" length="29" /><text>Triple Negative Breast Cancer</text></annotation><annotation id="23871"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="285" length="4" /><text>TNBC</text></annotation><annotation id="23872"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="227" length="5" /><text>human</text></annotation><annotation id="23873"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="389" length="4" /><text>TNBC</text></annotation><annotation id="23874"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="343" length="5" /><text>women</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>756</offset><text>Triple Negative Breast Cancer (TNBC) is a subtype of breast cancer that based on immunohistochemistry (IHC) is estrogens receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is characterized by its unique molecular profile, aggressive nature, distinct metastatic patterns and lack of targeted therapies. It is estimated that out of the worldwide breast cancer burden, approximately 170,000 cases are TNBC and account for ~10-20% of invasive breast cancers.</text><annotation id="23875"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="887" length="2" /><text>ER</text></annotation><annotation id="23876"><infon key="identifier">5241</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">713</infon><location offset="901" length="21" /><text>progesterone receptor</text></annotation><annotation id="23877"><infon key="identifier">5241</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">713</infon><location offset="924" length="2" /><text>PR</text></annotation><annotation id="23878"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="947" length="34" /><text>epidermal growth factor receptor 2</text></annotation><annotation id="23879"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="983" length="4" /><text>HER2</text></annotation><annotation id="23880"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="809" length="13" /><text>breast cancer</text></annotation><annotation id="23881"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1262" length="23" /><text>invasive breast cancers</text></annotation><annotation id="23882"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="787" length="4" /><text>TNBC</text></annotation><annotation id="23883"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="999" length="4" /><text>TNBC</text></annotation><annotation id="23884"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1176" length="13" /><text>breast cancer</text></annotation><annotation id="23885"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="1230" length="4" /><text>TNBC</text></annotation><annotation id="23886"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="941" length="5" /><text>human</text></annotation><annotation id="23887"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="756" length="29" /><text>Triple Negative Breast Cancer</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1287</offset><text>Molecular Profile and IHC Phenotype</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1323</offset><text>Breast cancers are typically classified into seven subtypes (3): luminal A (ER positive and histologic low grade), luminal B (ER positive and histologic high grade), HER2 overexpressing, basal-like (2 types - BL1 and BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL) and normal breast-like tumours. Majority of the TNBC are the basal-like subtype, and many basal-like breast cancers are triple negative; they are not equivalent in terms of gene expression signatures and IHC analysis. Basal-like breast cancer is a classification based on gene expression profiling. Although they appear to be synonymous, there is up to 30% discordance between the two groups. In addition to low expression of ER, PR and HER2, basal-like breast cancers are characterized by a high expression of CK5, CK14, caveolin-1, caix, p63, EGFR (Epidermal Growth Factor Receptor)/HER1, which reflects on the mammary gland basal/myoepithelial cell component.</text><annotation id="23888"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="1399" length="2" /><text>ER</text></annotation><annotation id="23889"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="1449" length="2" /><text>ER</text></annotation><annotation id="23890"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="1489" length="4" /><text>HER2</text></annotation><annotation id="23891"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="2040" length="2" /><text>ER</text></annotation><annotation id="23892"><infon key="identifier">5241</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">713</infon><location offset="2044" length="2" /><text>PR</text></annotation><annotation id="23893"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="2051" length="4" /><text>HER2</text></annotation><annotation id="23894"><infon key="identifier">3852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55461</infon><location offset="2125" length="3" /><text>CK5</text></annotation><annotation id="23895"><infon key="identifier">3861</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">110439</infon><location offset="2130" length="4" /><text>CK14</text></annotation><annotation id="23896"><infon key="identifier">857</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1330</infon><location offset="2136" length="10" /><text>caveolin-1</text></annotation><annotation id="23897"><infon key="identifier">768</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20325</infon><location offset="2148" length="4" /><text>caix</text></annotation><annotation id="23898"><infon key="identifier">8626</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31189</infon><location offset="2154" length="3" /><text>p63</text></annotation><annotation id="23899"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="2159" length="4" /><text>EGFR</text></annotation><annotation id="23900"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="2165" length="32" /><text>Epidermal Growth Factor Receptor</text></annotation><annotation id="23901"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="2199" length="4" /><text>HER1</text></annotation><annotation id="23902"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1832" length="24" /><text>Basal-like breast cancer</text></annotation><annotation id="23903"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="1662" length="4" /><text>TNBC</text></annotation><annotation id="23904"><infon key="identifier">MESH:C535700</infon><infon key="type">Disease</infon><location offset="1586" length="17" /><text>mesenchymal stem-</text></annotation><annotation id="23905"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="2057" length="25" /><text>basal-like breast cancers</text></annotation><annotation id="23906"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1618" length="26" /><text>normal breast-like tumours</text></annotation><annotation id="23907"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1704" length="25" /><text>basal-like breast cancers</text></annotation><annotation id="23908"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1323" length="14" /><text>Breast cancers</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2279</offset><text>Additionally, several proteins integrally involved in DNA repair are aberrantly expressed in TNBC, which may have implications on sensitivity to chemotherapeutic agents like, platinum-based drugs. High p53 IHC expression is common in basal-like breast cancer. Several additional and targetable molecular pathways implicated in the pathogenesis of basal-like breast cancer include the mutagen activated protein (MAP) kinase pathway, the Akt pathway, and the poly ADP-ribose polymerase1 (PARP1) pathway.</text><annotation id="23909"><infon key="identifier">7157</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">460</infon><location offset="2481" length="3" /><text>p53</text></annotation><annotation id="23910"><infon key="identifier">207</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3785</infon><location offset="2715" length="3" /><text>Akt</text></annotation><annotation id="23911"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="2736" length="27" /><text>poly ADP-ribose polymerase1</text></annotation><annotation id="23912"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="2765" length="5" /><text>PARP1</text></annotation><annotation id="23913"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="2513" length="24" /><text>basal-like breast cancer</text></annotation><annotation id="23914"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="2372" length="4" /><text>TNBC</text></annotation><annotation id="23915"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="2454" length="8" /><text>platinum</text></annotation><annotation id="23916"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="2626" length="24" /><text>basal-like breast cancer</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2781</offset><text>Association with BRCA1 Mutation status</text><annotation id="23917"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="2798" length="5" /><text>BRCA1</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2820</offset><text>It has been observed that a high percentage of BRCA1- associated hereditary and sporadic breast cancers are triple negative and express a high proportion of basal like cytokeratins (CK5,14,17), as well as P-Cadherin and HER1/EGFR. Gene expression studies support this association among patients with BRCA1 mutations that breast tumours tend to cluster within the basal like category.</text><annotation id="23918"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="3040" length="4" /><text>HER1</text></annotation><annotation id="23919"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="3045" length="4" /><text>EGFR</text></annotation><annotation id="23920"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="3120" length="5" /><text>BRCA1</text></annotation><annotation id="23922"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3106" length="8" /><text>patients</text></annotation><annotation id="23923"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="2867" length="56" /><text>BRCA1- associated hereditary and sporadic breast cancers</text></annotation><annotation id="23924"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="3141" length="14" /><text>breast tumours</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>3204</offset><text>Epidemiology and Risk Factors</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3234</offset><text>Several large scale population based studies indicate that TNBC are up to three times more likely to occur among pre-menopausal women of African-American descent. Certain epidemiologic studies like the Carolina Breast Cancer Study illustrated that as compared to the luminal a tumours, basal-like tumours were more likely to arise among women with early menarche, higher parity, younger age at full term pregnancy, and shorter duration of breast feeding, higher body mass index, and higher waist to hip ratio, especially among pre-menopausal patients. Another study done by Bauer et al. found that younger, non-Hispanic black and Hispanic women diagnosed with TNBC, had tumours that were more aggressive, and these women had poorer survival regardless of stage. In addition, non-Hispanic black women with late stage TNBC had the poorest survival of any comparable group.</text><annotation id="23925"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="3894" length="4" /><text>TNBC</text></annotation><annotation id="23926"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3362" length="5" /><text>women</text></annotation><annotation id="23927"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3776" length="8" /><text>patients</text></annotation><annotation id="23928"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3873" length="5" /><text>women</text></annotation><annotation id="23929"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="4050" length="4" /><text>TNBC</text></annotation><annotation id="23930"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="3501" length="17" /><text>luminal a tumours</text></annotation><annotation id="23931"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="3445" length="13" /><text>Breast Cancer</text></annotation><annotation id="23932"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4028" length="5" /><text>women</text></annotation><annotation id="23933"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3949" length="5" /><text>women</text></annotation><annotation id="23934"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3571" length="5" /><text>women</text></annotation><annotation id="23935"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="3293" length="4" /><text>TNBC</text></annotation><annotation id="23936"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="3520" length="18" /><text>basal-like tumours</text></annotation><annotation id="23937"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="3904" length="7" /><text>tumours</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>4105</offset><text>Clinical Characteristics</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4130</offset><text>TNBC is well known for its aggressive behaviour and is characterized by onset at a younger age, high mean tumour size, higher grade tumours and sometimes, a higher rate of node positivity. Additionally, this group is also known for an early peak of recurrence between the first and third year after diagnosis, and more aggressive metastases which are more likely to occur in viscera particularly in the lungs and brain, and less likely to spread to the bone. Based upon histological findings the majority of the triple negative breast cancers are of ductal origin; however, several other aggressive phenotypes also appear to be over represented, including metaplastic, apocrine and adenoid cystic. A histological study of basal-like tumours, all being ER/HER2 negative, yielded marked increase in mitotic count, geographic necrosis, pushing borders of invasion and stromal lymphocytic response.</text><annotation id="23938"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="4882" length="2" /><text>ER</text></annotation><annotation id="23939"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="4885" length="4" /><text>HER2</text></annotation><annotation id="23940"><infon key="identifier">MESH:D003528</infon><infon key="type">Disease</infon><location offset="4812" length="14" /><text>adenoid cystic</text></annotation><annotation id="23941"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="4460" length="10" /><text>metastases</text></annotation><annotation id="23942"><infon key="identifier">MESH:D009336</infon><infon key="type">Disease</infon><location offset="4953" length="8" /><text>necrosis</text></annotation><annotation id="23943"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="4262" length="7" /><text>tumours</text></annotation><annotation id="23944"><infon key="identifier">MESH:D057091</infon><infon key="type">Disease</infon><location offset="4799" length="8" /><text>apocrine</text></annotation><annotation id="23945"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="4236" length="6" /><text>tumour</text></annotation><annotation id="23946"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="4130" length="4" /><text>TNBC</text></annotation><annotation id="23947"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="4852" length="18" /><text>basal-like tumours</text></annotation><annotation id="23948"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="4642" length="30" /><text>triple negative breast cancers</text></annotation><annotation id="23949"><infon key="type">Disease</infon><location offset="4786" length="11" /><text>metaplastic</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>5025</offset><text>Prognosis</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5035</offset><text>An inferior prognosis in the basal-like breast cancer, as compared to the luminal type, has been uniformly demonstrated by a variety of studies. Population based studies have also demonstrated similar results with reduced breast cancer specific survival among those with TNBC, as compared with the luminal subtype.</text><annotation id="23950"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="5257" length="13" /><text>breast cancer</text></annotation><annotation id="23951"><infon key="type">Disease</infon><location offset="5333" length="7" /><text>luminal</text></annotation><annotation id="23952"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="5306" length="4" /><text>TNBC</text></annotation><annotation id="23953"><infon key="type">Disease</infon><location offset="5109" length="7" /><text>luminal</text></annotation><annotation id="23954"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="5064" length="24" /><text>basal-like breast cancer</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5350</offset><text>A recently reported Canadian series evaluating prognosis in over 1,500 women, showed an increased likelihood of distant recurrence and death among women with triple negative breast cancer, as compared to the non triple negative disease. Studies have consistently shown that more aggressive visceral and soft tissue relapses are more common and bone relapses less common among those diagnosed with triple negative versus ER positive disease. An estimated 15% of all patients with breast cancer will develop brain metastasis. In a series of over 3,000 patients with brain metastasis arising from breast cancer treated from 1989 to 2006, multivariate analysis indicated that triple negative status was the greatest risk factor for the development of cerebral metastasis (odds ratio=4.16; p&lt;0.001), above that of HER2 positive status (OR=3.43; p=0.005). In another study using patients with BRCA1 mutation, there was 82% complete pathologic response in those treated with Cisplatinum alone.</text><annotation id="23955"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="5770" length="2" /><text>ER</text></annotation><annotation id="23956"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="6159" length="4" /><text>HER2</text></annotation><annotation id="23957"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="6237" length="5" /><text>BRCA1</text></annotation><annotation id="23958"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="5944" length="13" /><text>breast cancer</text></annotation><annotation id="23959"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="6318" length="11" /><text>Cisplatinum</text></annotation><annotation id="23960"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="6097" length="19" /><text>cerebral metastasis</text></annotation><annotation id="23961"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5421" length="5" /><text>women</text></annotation><annotation id="23962"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="5485" length="5" /><text>death</text></annotation><annotation id="23963"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="6223" length="8" /><text>patients</text></annotation><annotation id="23964"><infon key="identifier">MESH:D012008</infon><infon key="type">Disease</infon><location offset="5470" length="10" /><text>recurrence</text></annotation><annotation id="23965"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="5914" length="16" /><text>brain metastasis</text></annotation><annotation id="23966"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5815" length="8" /><text>patients</text></annotation><annotation id="23967"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="5856" length="16" /><text>brain metastasis</text></annotation><annotation id="23968"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5497" length="5" /><text>women</text></annotation><annotation id="23969"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5900" length="8" /><text>patients</text></annotation><annotation id="23970"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="5524" length="13" /><text>breast cancer</text></annotation><annotation id="23971"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="5829" length="13" /><text>breast cancer</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>6337</offset><text>Therapeutic Strategies</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6360</offset><text>Although triple negative breast cancers are associated with a generally poor breast cancer specific outcome, most are not resistant to chemotherapy. These patients have an extremely poor prognosis and relapse and die quickly. Several therapies are being developed that target specific biomarkers of TNBC or basal-like subtype. These strategies include EGFR-targeted agents, androgen receptor targeted agents, anti-antigenic agents, and PARP inhibitors are offering an option in triple negative disease; however, their uses as of date are limited to clinical trials and more work is needed to identify targets that yield high therapeutic ratios. TNBC with BRCA1 gene mutations may be more sensitive to agents that cause DNA damage, such as Cisplatin. Other, more recent promising therapeutic targets for TNBC include the NOTCH, Hedgehog and Wnt/b-Catenin signalling pathways. Studies have shown that these therapies alter the apoptotic pathway, inhibiting tumour progression.</text><annotation id="23972"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="6712" length="4" /><text>EGFR</text></annotation><annotation id="23973"><infon key="identifier">367</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">28</infon><location offset="6734" length="17" /><text>androgen receptor</text></annotation><annotation id="23974"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="6796" length="4" /><text>PARP</text></annotation><annotation id="23975"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="7015" length="5" /><text>BRCA1</text></annotation><annotation id="23976"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location offset="7204" length="9" /><text>b-Catenin</text></annotation><annotation id="23977"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="7315" length="6" /><text>tumour</text></annotation><annotation id="23978"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="7163" length="4" /><text>TNBC</text></annotation><annotation id="23979"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="6659" length="4" /><text>TNBC</text></annotation><annotation id="23980"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="7099" length="9" /><text>Cisplatin</text></annotation><annotation id="23981"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="6515" length="8" /><text>patients</text></annotation><annotation id="23982"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="6437" length="13" /><text>breast cancer</text></annotation><annotation id="23983"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="6369" length="30" /><text>triple negative breast cancers</text></annotation><annotation id="23984"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="7005" length="4" /><text>TNBC</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>7335</offset><text>Chemotherapy</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7348</offset><text>Adjuvant chemotherapy has been shown to not only prolong disease-free survival in patients but overall survival as a whole; however, TNBC lacks the typical targeted receptors found in luminal or HER-2 disease and therefore cannot be treated with hormonal agents, such as SERMS, aromatise inhibitors or HER2 antagonists. To combat this issue several neoadjuvant studies have been done which accentuated the relationship between chemo sensitivity and outcome, revealing proportionally higher sensitivity to anthracycline or anthracycline/taxane-based chemotherapy such as Doxorubicin and Cyclophosphamide (standard chemotherapeutic agents), for basal like/ER negative breast cancers as compared to the luminal subtype. Highest response rates were noticed among those classified as basal like (85%) and HER2 positive (70%), as compared to luminal (47%, p&lt;0.0001). Despite initial chemo sensitivity, disease free survival (p=0.04) and overall survival (p=0.02) remained poorest among those with basal like and HER2 positive tumours, compared to the luminal subtype. Although triple negative disease is highly responsive to Anthracycline/Taxane chemotherapy treatment, a high risk of relapse still remains if the tumour is not completely eradicated.</text><annotation id="23985"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="7543" length="5" /><text>HER-2</text></annotation><annotation id="23986"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="7650" length="4" /><text>HER2</text></annotation><annotation id="23987"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="8002" length="2" /><text>ER</text></annotation><annotation id="23988"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="8148" length="4" /><text>HER2</text></annotation><annotation id="23989"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="8354" length="4" /><text>HER2</text></annotation><annotation id="23990"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="8556" length="6" /><text>tumour</text></annotation><annotation id="23991"><infon key="identifier">MESH:D018943</infon><infon key="type">Chemical</infon><location offset="7853" length="13" /><text>anthracycline</text></annotation><annotation id="23992"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="8368" length="7" /><text>tumours</text></annotation><annotation id="23993"><infon key="identifier">MESH:D002280</infon><infon key="type">Disease</infon><location offset="7991" length="10" /><text>basal like</text></annotation><annotation id="23994"><infon key="type">Disease</infon><location offset="8184" length="7" /><text>luminal</text></annotation><annotation id="23995"><infon key="type">Disease</infon><location offset="8048" length="7" /><text>luminal</text></annotation><annotation id="23996"><infon key="identifier">MESH:C080625</infon><infon key="type">Chemical</infon><location offset="8481" length="6" /><text>Taxane</text></annotation><annotation id="23997"><infon key="type">Disease</infon><location offset="7532" length="7" /><text>luminal</text></annotation><annotation id="23998"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="7481" length="4" /><text>TNBC</text></annotation><annotation id="23999"><infon key="identifier">MESH:D018943</infon><infon key="type">Chemical</infon><location offset="7870" length="13" /><text>anthracycline</text></annotation><annotation id="24000"><infon key="identifier">MESH:C080625</infon><infon key="type">Chemical</infon><location offset="7884" length="6" /><text>taxane</text></annotation><annotation id="24001"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="7918" length="11" /><text>Doxorubicin</text></annotation><annotation id="24002"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="7626" length="20" /><text>aromatise inhibitors</text></annotation><annotation id="24003"><infon key="identifier">MESH:D003520</infon><infon key="type">Chemical</infon><location offset="7934" length="16" /><text>Cyclophosphamide</text></annotation><annotation id="24004"><infon key="identifier">MESH:D002280</infon><infon key="type">Disease</infon><location offset="8339" length="10" /><text>basal like</text></annotation><annotation id="24005"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="8014" length="14" /><text>breast cancers</text></annotation><annotation id="24006"><infon key="identifier">MESH:D018943</infon><infon key="type">Chemical</infon><location offset="8467" length="13" /><text>Anthracycline</text></annotation><annotation id="24007"><infon key="identifier">MESH:D002280</infon><infon key="type">Disease</infon><location offset="8127" length="10" /><text>basal like</text></annotation><annotation id="24008"><infon key="type">Disease</infon><location offset="8393" length="7" /><text>luminal</text></annotation><annotation id="24009"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="7430" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8595</offset><text>Additionally, pre-clinical and clinical studies indicate that tumours with BRCA1 dysfunction are sensitive to platinum agents such as Cisplatin, and Carboplatin which function by causing DNA damage and promote tumour cell apoptosis. Studies have shown that p63, a family member of p53, is responsible for controlling a survival pathway that directly mediates Cisplatin sensitivity in TNBC; it therefore, can possibly be used as a biomarker to predict response to platinum therapy in triple negative breast cancer. However, this finding warrants further investigation and currently platinum's are not recommended for the adjuvant treatment of TNBC.</text><annotation id="24010"><infon key="identifier">8626</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31189</infon><location offset="8852" length="3" /><text>p63</text></annotation><annotation id="24011"><infon key="identifier">7157</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">460</infon><location offset="8876" length="3" /><text>p53</text></annotation><annotation id="24013"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="8805" length="6" /><text>tumour</text></annotation><annotation id="24014"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="8729" length="9" /><text>Cisplatin</text></annotation><annotation id="24015"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="9176" length="8" /><text>platinum</text></annotation><annotation id="24016"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="9078" length="29" /><text>triple negative breast cancer</text></annotation><annotation id="24017"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="8705" length="8" /><text>platinum</text></annotation><annotation id="24018"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="9237" length="4" /><text>TNBC</text></annotation><annotation id="24019"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="8954" length="9" /><text>Cisplatin</text></annotation><annotation id="24020"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="9058" length="8" /><text>platinum</text></annotation><annotation id="24021"><infon key="identifier">OMIM:604370</infon><infon key="type">Disease</infon><location offset="8670" length="17" /><text>BRCA1 dysfunction</text></annotation><annotation id="24022"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="8744" length="11" /><text>Carboplatin</text></annotation><annotation id="24023"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="8657" length="7" /><text>tumours</text></annotation><annotation id="24024"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="8979" length="4" /><text>TNBC</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>9245</offset><text>EGFR Inhibitors</text><annotation id="24025"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="9245" length="4" /><text>EGFR</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9261</offset><text>EGFR expression is approximately seen in 60% of triple negative breast tumors, thus providing a reasonable targeted treatment approach. A phase II trial evaluating the combination of Cetuximab (a chimeric monoclonal antibody targeting EGFR) and Carboplatin, weekly for 3 to 4 weeks reported a response rate of 18% and overall clinical benefit of 27% among 102 patients with advanced TNBC.</text><annotation id="24026"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="9261" length="4" /><text>EGFR</text></annotation><annotation id="24027"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="9496" length="4" /><text>EGFR</text></annotation><annotation id="24028"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="9644" length="4" /><text>TNBC</text></annotation><annotation id="24029"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="9506" length="11" /><text>Carboplatin</text></annotation><annotation id="24030"><infon key="identifier">MESH:D000068818</infon><infon key="type">Chemical</infon><location offset="9444" length="9" /><text>Cetuximab</text></annotation><annotation id="24031"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="9621" length="8" /><text>patients</text></annotation><annotation id="24032"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="9325" length="13" /><text>breast tumors</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9650</offset><text>Another study evaluating the combination of Irinotecan and Carboplatin with or without Cetuximab reported response rates of 49% and 30% respectively, among 72 patients with pre-treated TNBC. EGFR inhibitor Panitumumab, when used in combination with standard chemotherapeutic agents for neoadjuvant therapy for inoperable TNBC was recently reported to have shown a pathological complete response rate of 65%. Other studies have recently demonstrated that EGFR inhibitors when used in combination with Texans or platinum's may increase the efficacy of the other agents. To date, the majority of data with EGFR inhibitors has generally been interpreted as negative.</text><annotation id="24033"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="9841" length="4" /><text>EGFR</text></annotation><annotation id="24034"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="10104" length="4" /><text>EGFR</text></annotation><annotation id="24035"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="10253" length="4" /><text>EGFR</text></annotation><annotation id="24036"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="9809" length="8" /><text>patients</text></annotation><annotation id="24037"><infon key="identifier">MESH:D000077544</infon><infon key="type">Chemical</infon><location offset="9856" length="11" /><text>Panitumumab</text></annotation><annotation id="24038"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="9835" length="4" /><text>TNBC</text></annotation><annotation id="24039"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="9709" length="11" /><text>Carboplatin</text></annotation><annotation id="24040"><infon key="identifier">MESH:D000077146</infon><infon key="type">Chemical</infon><location offset="9694" length="10" /><text>Irinotecan</text></annotation><annotation id="24041"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="9971" length="4" /><text>TNBC</text></annotation><annotation id="24042"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="10150" length="6" /><text>Texans</text></annotation><annotation id="24043"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="10160" length="8" /><text>platinum</text></annotation><annotation id="24044"><infon key="identifier">MESH:D000068818</infon><infon key="type">Chemical</infon><location offset="9737" length="9" /><text>Cetuximab</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>10315</offset><text>PARP Inhibitors</text><annotation id="24045"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="10315" length="4" /><text>PARP</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10331</offset><text>PARP1, a gene that encodes an enzyme involved in the molecular events leading to cell recovery from DNA damage, when inhibited, leads to the accumulation of double-stranded DNA breaks. Cells deficient in BRCA1 and BRCA2 (required for normal homologous recombination), are exquisitely sensitive to PARP1 inhibition. Several PARP inhibitors Olaparib, Velaparib and PF-01367338 are currently in clinical trials and hold a promising future. The study demonstrated a statistically significant 50% reduction in the risk of death; however, phase III trials failed to show statistically significant benefit for this combination, hence, the drug has been discontinued but some biomarker analysis is still underway to determine if a specific subset of patient may benefit from the drug. This therefore highlights the need for continued research and clinical trials.</text><annotation id="24046"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="10331" length="5" /><text>PARP1</text></annotation><annotation id="24047"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="10535" length="5" /><text>BRCA1</text></annotation><annotation id="24048"><infon key="identifier">675</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41</infon><location offset="10545" length="5" /><text>BRCA2</text></annotation><annotation id="24049"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="10628" length="5" /><text>PARP1</text></annotation><annotation id="24050"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="10654" length="4" /><text>PARP</text></annotation><annotation id="24051"><infon key="identifier">MESH:C531549</infon><infon key="type">Chemical</infon><location offset="10694" length="11" /><text>PF-01367338</text></annotation><annotation id="24052"><infon key="identifier">MESH:C531550</infon><infon key="type">Chemical</infon><location offset="10670" length="8" /><text>Olaparib</text></annotation><annotation id="24053"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="10848" length="5" /><text>death</text></annotation><annotation id="24054"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="10680" length="9" /><text>Velaparib</text></annotation><annotation id="24055"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11073" length="7" /><text>patient</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>11187</offset><text>Antiangiogenic Agents</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11209</offset><text>The antiangiogenic agent Bevacizumab, a monoclonal antibody that targets all forms of VEGF, has been evaluated in a number of large phase III trials as treatment of metastatic breast cancer. The landmark study E2100 illustrated improvement in progressionfree survival (11.8 vs. 5.9 months, HR=0.60, p&lt;0.001) when adding Bevacizumab to Paclitaxel chemotherapy compared with single-agent Paclitaxel alone in first-line treatment of metastatic disease. This subsequently led to subgroup analysis that demonstrated similar progression free survival benefits in both patients with TNBC and non-TNBC with the use of Bevacizumab plus a taxane. Currently, the BEATRICE trial is prospectively investigating this combination as adjuvant therapy in TNBC. Additionally, several small-molecule inhibitors of the VEGF pathway appear to have activity in the subset of pre-treated triple-negative breast cancer and definitive studies showing overall survival benefit will be needed prior to re approval.</text><annotation id="24056"><infon key="identifier">7422</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2534</infon><location offset="11295" length="4" /><text>VEGF</text></annotation><annotation id="24057"><infon key="identifier">7422</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2534</infon><location offset="12008" length="4" /><text>VEGF</text></annotation><annotation id="24058"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="11785" length="4" /><text>TNBC</text></annotation><annotation id="24059"><infon key="identifier">MESH:D000068258</infon><infon key="type">Chemical</infon><location offset="11819" length="11" /><text>Bevacizumab</text></annotation><annotation id="24060"><infon key="identifier">MESH:D017239</infon><infon key="type">Chemical</infon><location offset="11544" length="10" /><text>Paclitaxel</text></annotation><annotation id="24061"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="11798" length="4" /><text>TNBC</text></annotation><annotation id="24062"><infon key="identifier">MESH:D000068258</infon><infon key="type">Chemical</infon><location offset="11529" length="11" /><text>Bevacizumab</text></annotation><annotation id="24063"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11771" length="8" /><text>patients</text></annotation><annotation id="24064"><infon key="identifier">MESH:C080625</infon><infon key="type">Chemical</infon><location offset="11838" length="6" /><text>taxane</text></annotation><annotation id="24065"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="11385" length="13" /><text>breast cancer</text></annotation><annotation id="24066"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="12090" length="13" /><text>breast cancer</text></annotation><annotation id="24067"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="11947" length="4" /><text>TNBC</text></annotation><annotation id="24068"><infon key="identifier">MESH:D000068258</infon><infon key="type">Chemical</infon><location offset="11234" length="11" /><text>Bevacizumab</text></annotation><annotation id="24069"><infon key="identifier">MESH:D017239</infon><infon key="type">Chemical</infon><location offset="11595" length="10" /><text>Paclitaxel</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>12197</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>12208</offset><text>In conclusion, TNBC is a difficult and complex disease entity that is both confusing and frustrating for researchers, physicians and patients. To date there are multiple approaches attempting to improve care of triple negative breast cancer patients, including DNA damaging agents like platinum's, targeted EGFR and VEGF inhibitors, and, PARP inhibitors; however, none have been as clinically successful as anticipated and more targeted therapies need to be developed and explored. The Wnt/b-Catenin, NOTCH and Hedgehog signaling pathways are being considered as novel therapeutic targets for TNBC.</text><annotation id="24070"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="12515" length="4" /><text>EGFR</text></annotation><annotation id="24071"><infon key="identifier">7422</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2534</infon><location offset="12524" length="4" /><text>VEGF</text></annotation><annotation id="24072"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="12546" length="4" /><text>PARP</text></annotation><annotation id="24073"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location offset="12698" length="9" /><text>b-Catenin</text></annotation><annotation id="24074"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="12494" length="8" /><text>platinum</text></annotation><annotation id="24075"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12449" length="8" /><text>patients</text></annotation><annotation id="24076"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="12801" length="4" /><text>TNBC</text></annotation><annotation id="24077"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="12223" length="4" /><text>TNBC</text></annotation><annotation id="24078"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12341" length="8" /><text>patients</text></annotation><annotation id="24079"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="12435" length="13" /><text>breast cancer</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>12809</offset><text>Future Direction</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>12826</offset><text>The key to developing targeted therapies for TNBC will depend on understanding the molecular mechanism for the development of these cancers. There are seminal studies by Hosey et al. and by our group (unpublished results) on the possible molecular mechanisms of BRCA1 dysfunction which could result in ER negative breast cancers. Recently Ubc9, a sole SUMO-E2-conjugating enzyme for sumoylation was found to bind BRCA1 proteins and ferry it to the nucleus unlike disease associated mutant BRCA1 proteins. Over expression of Ubc9 was observed in breast tumours and TNBC cell lines. BRCA1 function-based cellular assays have been designed to detect loss of binding to Ubc9 by BRCA1 mutants (Patent number US 8,372,580). These assays not only predict the risk for developing TNBC but may also lead to the development of targeted therapies for hereditary and sporadic TNBC.</text><annotation id="24080"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="13088" length="5" /><text>BRCA1</text></annotation><annotation id="24081"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="13128" length="2" /><text>ER</text></annotation><annotation id="24082"><infon key="identifier">7329</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5574</infon><location offset="13165" length="4" /><text>Ubc9</text></annotation><annotation id="24083"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="13239" length="5" /><text>BRCA1</text></annotation><annotation id="24084"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="13315" length="5" /><text>BRCA1</text></annotation><annotation id="24085"><infon key="identifier">7329</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5574</infon><location offset="13350" length="4" /><text>Ubc9</text></annotation><annotation id="24086"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="13407" length="5" /><text>BRCA1</text></annotation><annotation id="24087"><infon key="identifier">7329</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5574</infon><location offset="13492" length="4" /><text>Ubc9</text></annotation><annotation id="24088"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="13500" length="5" /><text>BRCA1</text></annotation><annotation id="24089"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="12871" length="4" /><text>TNBC</text></annotation><annotation id="24090"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="12958" length="7" /><text>cancers</text></annotation><annotation id="24091"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="13371" length="14" /><text>breast tumours</text></annotation><annotation id="24092"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="13666" length="28" /><text>hereditary and sporadic TNBC</text></annotation><annotation id="24093"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="13140" length="14" /><text>breast cancers</text></annotation><annotation id="24094"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="13390" length="4" /><text>TNBC</text></annotation><annotation id="24095"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="13598" length="4" /><text>TNBC</text></annotation></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>13696</offset><text>References</text></passage><passage><infon key="volume">16</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Perou;given-names:CM</infon><infon key="fpage">61</infon><infon key="issue">Suppl 1</infon><infon key="pub-id_pmid">21278442</infon><infon key="year">2011</infon><infon key="source">Oncologist</infon><infon key="type">ref</infon><infon key="lpage">70</infon><offset>13707</offset><text>Molecular stratification of triple-negative breast cancers</text></passage><passage><infon key="name_3">surname:West;given-names:R</infon><infon key="name_2">surname:Millar;given-names:EK</infon><infon key="name_1">surname:Beith;given-names:JM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:O'Toole;given-names:SA</infon><infon key="year">2013</infon><infon key="source">J Clin Pathol</infon><infon key="type">ref</infon><infon key="name_4">surname:McLean;given-names:A</infon><offset>13766</offset><text>Therapeutic targets in triple negative breast cancer</text></passage><passage><infon key="name_3">surname:Sanders;given-names:ME</infon><infon key="name_2">surname:Chen;given-names:X</infon><infon key="name_1">surname:Bauer;given-names:JA</infon><infon key="name_0">surname:Lehmann;given-names:BD</infon><infon key="fpage">2750</infon><infon key="pub-id_pmid">21633166</infon><infon key="year">2011</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="volume">121</infon><infon key="section_type">REF</infon><infon key="lpage">2767</infon><infon key="name_4">surname:Chakravarthy;given-names:AB</infon><offset>13819</offset><text>Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</text></passage><passage><infon key="volume">363</infon><infon key="name_2">surname:Reis-Filho;given-names:JS</infon><infon key="name_1">surname:Smith;given-names:IE</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Foulkes;given-names:WD</infon><infon key="fpage">1938</infon><infon key="pub-id_pmid">21067385</infon><infon key="year">2010</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">1948</infon><offset>13941</offset><text>Triple-negative breast cancer</text></passage><passage><infon key="name_3">surname:Esterni;given-names:B</infon><infon key="name_2">surname:Cervera;given-names:N</infon><infon key="name_1">surname:Finetti;given-names:P</infon><infon key="name_0">surname:Bertucci;given-names:F</infon><infon key="fpage">236</infon><infon key="pub-id_pmid">18398844</infon><infon key="year">2008</infon><infon key="source">Int J Cancer</infon><infon key="type">ref</infon><infon key="volume">123</infon><infon key="section_type">REF</infon><infon key="lpage">240</infon><infon key="name_4">surname:Hermitte;given-names:F</infon><offset>13971</offset><text>How basal are triple-negative breast cancers?</text></passage><passage><infon key="name_3">surname:Cheang;given-names:M</infon><infon key="name_2">surname:Jensen;given-names:K</infon><infon key="name_1">surname:Hsu;given-names:FD</infon><infon key="name_0">surname:Nielsen;given-names:TO</infon><infon key="fpage">5367</infon><infon key="pub-id_pmid">15328174</infon><infon key="year">2004</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="section_type">REF</infon><infon key="lpage">5374</infon><infon key="name_4">surname:Karaca;given-names:G</infon><offset>14017</offset><text>Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</text></passage><passage><infon key="volume">26</infon><infon key="name_2">surname:Ellis;given-names:IO</infon><infon key="name_1">surname:Reis-Filho;given-names:JS</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rakha;given-names:EA</infon><infon key="fpage">2568</infon><infon key="pub-id_pmid">18487574</infon><infon key="year">2008</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="lpage">2581</infon><offset>14122</offset><text>Basal-like breast cancer: a critical review</text></passage><passage><infon key="name_3">surname:He;given-names:X</infon><infon key="volume">6</infon><infon key="name_2">surname:Oh;given-names:DS</infon><infon key="name_1">surname:Herschkowitz;given-names:JI</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Troester;given-names:MA</infon><infon key="fpage">276</infon><infon key="pub-id_pmid">17150101</infon><infon key="year">2006</infon><infon key="source">BMC Cancer</infon><infon key="type">ref</infon><infon key="name_4">surname:Hoadley;given-names:KA</infon><offset>14166</offset><text>Gene expression patterns associated with p53 status in breast cancer</text><annotation id="24096"><infon key="identifier">7157</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">460</infon><location offset="14207" length="3" /><text>p53</text></annotation></passage><passage><infon key="volume">3</infon><infon key="name_2">surname:Coombes;given-names:R</infon><infon key="name_1">surname:Heller;given-names:W</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Cleator;given-names:S</infon><infon key="fpage">235</infon><infon key="pub-id_pmid">17329194</infon><infon key="year">2007</infon><infon key="source">Lancet Oncol</infon><infon key="type">ref</infon><infon key="lpage">244</infon><offset>14235</offset><text>Triple-negative breast cancer: Therapeutic options</text></passage><passage><infon key="name_3">surname:Begin;given-names:LR</infon><infon key="name_2">surname:Chappuis;given-names:PO</infon><infon key="name_1">surname:Stefansson;given-names:IM</infon><infon key="name_0">surname:Foulkes;given-names:WD</infon><infon key="fpage">1482</infon><infon key="pub-id_pmid">14519755</infon><infon key="year">2003</infon><infon key="source">J Natl Cancer Inst</infon><infon key="type">ref</infon><infon key="volume">95</infon><infon key="section_type">REF</infon><infon key="lpage">1485</infon><infon key="name_4">surname:Goffin;given-names:JR</infon><offset>14286</offset><text>Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer</text><annotation id="24097"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="14295" length="5" /><text>BRCA1</text></annotation></passage><passage><infon key="volume">4</infon><infon key="name_2">surname:Ashworth;given-names:A</infon><infon key="name_1">surname:Tutt;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Turner;given-names:N</infon><infon key="fpage">814</infon><infon key="pub-id_pmid">15510162</infon><infon key="year">2004</infon><infon key="source">Nat Rev Cancer</infon><infon key="type">ref</infon><infon key="lpage">819</infon><offset>14361</offset><text>Hallmarks of 'BRCAness' in sporadic cancers</text></passage><passage><infon key="name_3">surname:Hastie;given-names:T</infon><infon key="name_2">surname:Parker;given-names:J</infon><infon key="name_1">surname:Tibshirani;given-names:R</infon><infon key="name_0">surname:Sorlie;given-names:T</infon><infon key="fpage">8418</infon><infon key="pub-id_pmid">12829800</infon><infon key="year">2003</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="volume">100</infon><infon key="section_type">REF</infon><infon key="lpage">8423</infon><infon key="name_4">surname:Marron;given-names:JS</infon><offset>14409</offset><text>Repeated observation of breast tumor subtypes in independent gene expression data sets</text></passage><passage><infon key="name_3">surname:Parise;given-names:CA</infon><infon key="name_2">surname:Cress;given-names:R</infon><infon key="name_1">surname:Brown;given-names:M</infon><infon key="name_0">surname:Bauer;given-names:K</infon><infon key="fpage">1721</infon><infon key="pub-id_pmid">17387718</infon><infon key="year">2007</infon><infon key="source">Cancer</infon><infon key="type">ref</infon><infon key="volume">109</infon><infon key="section_type">REF</infon><infon key="lpage">1728</infon><infon key="name_4">surname:Caggiano;given-names:V</infon><offset>14496</offset><text>Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer registry</text><annotation id="24098"><infon key="identifier">5241</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">713</infon><location offset="14553" length="21" /><text>progesterone receptor</text></annotation><annotation id="24099"><infon key="identifier">2064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3273</infon><location offset="14594" length="4" /><text>HER2</text></annotation><annotation id="24100"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="14520" length="17" /><text>estrogen receptor</text></annotation></passage><passage><infon key="name_3">surname:Dressler;given-names:LG</infon><infon key="name_2">surname:Livasy;given-names:CA</infon><infon key="name_1">surname:Perou;given-names:CM</infon><infon key="name_0">surname:Carey;given-names:LA</infon><infon key="fpage">2492</infon><infon key="pub-id_pmid">16757721</infon><infon key="year">2006</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">295</infon><infon key="section_type">REF</infon><infon key="lpage">2502</infon><infon key="name_4">surname:Cowan;given-names:D</infon><offset>14734</offset><text>Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study</text></passage><passage><infon key="volume">13</infon><infon key="name_2">surname:Hanna;given-names:WM</infon><infon key="name_1">surname:Pritchard;given-names:KI</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Dent;given-names:RTM</infon><infon key="fpage">4429</infon><infon key="pub-id_pmid">17671126</infon><infon key="year">2007</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="lpage">4434</infon><offset>14813</offset><text>Triple-negative breast cancer: Clinical features and patterns of recurrence</text></passage><passage><infon key="name_3">surname:Linn;given-names:SC</infon><infon key="name_2">surname:Schouten;given-names:PC</infon><infon key="name_1">surname:Azim;given-names:HA;suffix:Jr</infon><infon key="name_0">surname:Criscitiello;given-names:C</infon><infon key="fpage">vi13</infon><infon key="issue">suppl 6</infon><infon key="pub-id_pmid">23012296</infon><infon key="year">2012</infon><infon key="source">Ann Oncol</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="section_type">REF</infon><infon key="lpage">vi18</infon><infon key="name_4">surname:Sotiriou;given-names:C</infon><offset>14889</offset><text>Understanding the biology of triple-negative breast cancer</text></passage><passage><infon key="name_3">surname:Savage;given-names:K</infon><infon key="name_2">surname:Steele;given-names:D</infon><infon key="name_1">surname:Milanezi;given-names:F</infon><infon key="name_0">surname:Reis-Filho;given-names:JS</infon><infon key="fpage">10</infon><infon key="pub-id_pmid">16842242</infon><infon key="year">2006</infon><infon key="source">Histopathology</infon><infon key="type">ref</infon><infon key="volume">49</infon><infon key="section_type">REF</infon><infon key="lpage">21</infon><infon key="name_4">surname:Simpson;given-names:PT</infon><offset>14948</offset><text>Metaplastic breast carcinomas are basal-like tumours</text></passage><passage><infon key="name_3">surname:Tretiakova;given-names:MS</infon><infon key="name_2">surname:Nanda;given-names:R</infon><infon key="name_1">surname:Karaca;given-names:G</infon><infon key="name_0">surname:Livasy;given-names:CA</infon><infon key="fpage">264</infon><infon key="pub-id_pmid">16341146</infon><infon key="year">2006</infon><infon key="source">Mod Pathol</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="section_type">REF</infon><infon key="lpage">271</infon><infon key="name_4">surname:Olopade;given-names:OI</infon><offset>15001</offset><text>Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma</text></passage><passage><infon key="name_3">surname:Aas;given-names:T</infon><infon key="name_2">surname:Tibshirani;given-names:R</infon><infon key="name_1">surname:Perou;given-names:CM</infon><infon key="name_0">surname:Sorlie;given-names:T</infon><infon key="fpage">10869</infon><infon key="pub-id_pmid">11553815</infon><infon key="year">2001</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="volume">98</infon><infon key="section_type">REF</infon><infon key="lpage">10874</infon><infon key="name_4">surname:Geisler;given-names:S</infon><offset>15078</offset><text>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</text></passage><passage><infon key="name_3">surname:Sieuwerts;given-names:AM</infon><infon key="name_2">surname:Zhang;given-names:Y</infon><infon key="name_1">surname:Wang;given-names:Y</infon><infon key="name_0">surname:Smid;given-names:M</infon><infon key="fpage">3108</infon><infon key="pub-id_pmid">18451135</infon><infon key="year">2008</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="section_type">REF</infon><infon key="lpage">3114</infon><infon key="name_4">surname:Yu;given-names:J</infon><offset>15180</offset><text>Subtypes of breast cancer show preferential site of relapse</text></passage><passage><infon key="name_3">surname:Lueck;given-names:HJ</infon><infon key="volume">26</infon><infon key="name_2">surname:Traut;given-names:A</infon><infon key="name_1">surname:Harter;given-names:P</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Heitz;given-names:F</infon><infon key="fpage">43s</infon><infon key="year">2008</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="name_4">surname:Beutel;given-names:B</infon><offset>15240</offset><text>Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors (abstract 1010)</text></passage><passage><infon key="name_3">surname:Grzybowska;given-names:E</infon><infon key="name_2">surname:Huzarski;given-names:T</infon><infon key="name_1">surname:Gronwald;given-names:J</infon><infon key="name_0">surname:Byrski;given-names:T</infon><infon key="fpage">375</infon><infon key="pub-id_pmid">20008645</infon><infon key="year">2010</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="section_type">REF</infon><infon key="lpage">379</infon><infon key="name_4">surname:Budryk;given-names:M</infon><offset>15340</offset><text>Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy</text><annotation id="24101"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="15395" length="5" /><text>BRCA1</text></annotation></passage><passage><infon key="volume">23</infon><infon key="name_1">surname:Viale;given-names:G</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Penault;given-names:F</infon><infon key="fpage">vi19</infon><infon key="pub-id_pmid">23012297</infon><infon key="year">2012</infon><infon key="source">Ann Oncol</infon><infon key="type">ref</infon><infon key="lpage">vi22</infon><offset>15456</offset><text>Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective</text></passage><passage><infon key="name_3">surname:Chen;given-names:H</infon><infon key="name_2">surname:Liu;given-names:S</infon><infon key="name_1">surname:Timms;given-names:KM</infon><infon key="name_0">surname:Gonzalez-Angulo;given-names:AM</infon><infon key="fpage">1082</infon><infon key="pub-id_pmid">21233401</infon><infon key="year">2011</infon><infon key="source">Clinical Cancer Res</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="section_type">REF</infon><infon key="lpage">1089</infon><infon key="name_4">surname:Litton;given-names:JK</infon><offset>15550</offset><text>Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer</text></passage><passage><infon key="volume">23</infon><infon key="name_1">surname:Gligorov;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Joensuu;given-names:H</infon><infon key="fpage">vi40</infon><infon key="pub-id_pmid">23012301</infon><infon key="year">2012</infon><infon key="source">Ann Oncol</infon><infon key="type">ref</infon><infon key="lpage">vi45</infon><offset>15657</offset><text>Adjuvant treatments for triple-negative breast cancers</text></passage><passage><infon key="name_3">surname:Gatti;given-names:L</infon><infon key="name_2">surname:Sawyer;given-names:L</infon><infon key="name_1">surname:Dees;given-names:E</infon><infon key="name_0">surname:Carey;given-names:L</infon><infon key="fpage">2329</infon><infon key="pub-id_pmid">17438091</infon><infon key="year">2007</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="section_type">REF</infon><infon key="lpage">2334</infon><infon key="name_4">surname:Moore;given-names:DT</infon><offset>15712</offset><text>The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes</text></passage><passage><infon key="section_type">REF</infon><infon key="year">2011</infon><infon key="type">ref</infon><offset>15798</offset><text>Sanofi breast cancer drug flunks Phase III trial</text></passage><passage><infon key="name_2">surname:Marcom;given-names:PK</infon><infon key="name_1">surname:Rugo;given-names:HS</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Carey;given-names:LA</infon><infon key="year">2009</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><offset>15847</offset><text>EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. (Abstract 1009)</text><annotation id="24102"><infon key="identifier">1956</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74545</infon><location offset="15847" length="4" /><text>EGFR</text></annotation></passage><passage><infon key="name_3">surname:Hodgson;given-names:SV</infon><infon key="name_2">surname:Ameziane;given-names:N</infon><infon key="name_1">surname:Tischkowitz;given-names:M</infon><infon key="name_0">surname:Taniguchi;given-names:T</infon><infon key="fpage">568</infon><infon key="pub-id_pmid">12692539</infon><infon key="year">2003</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="section_type">REF</infon><infon key="lpage">574</infon><infon key="name_4">surname:Mathew;given-names:CG</infon><offset>15973</offset><text>Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors</text></passage><passage><infon key="name_3">surname:Holway;given-names:VW</infon><infon key="name_2">surname:Pesenti;given-names:E</infon><infon key="name_1">surname:Murray;given-names:LJ</infon><infon key="name_0">surname:Abrams;given-names:TJ</infon><infon key="fpage">1011</infon><infon key="pub-id_pmid">14578466</infon><infon key="year">2003</infon><infon key="source">Mol Cancer Ther</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="section_type">REF</infon><infon key="lpage">1021</infon><infon key="name_4">surname:Colombo;given-names:T</infon><offset>16057</offset><text>Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with"standard of care" therapeutic agents for the treatment of breast cancer</text></passage><passage><infon key="name_3">surname:Cobleigh;given-names:MA</infon><infon key="name_2">surname:Rugo;given-names:HS</infon><infon key="name_1">surname:Elias;given-names:AD</infon><infon key="name_0">surname:Burstein;given-names:HJ</infon><infon key="fpage">1810</infon><infon key="pub-id_pmid">18347007</infon><infon key="year">2008</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="section_type">REF</infon><infon key="lpage">1816</infon><infon key="name_4">surname:Wolff;given-names:AC</infon><offset>16237</offset><text>Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane</text></passage><passage><infon key="name_3">surname:Quinn;given-names:JE</infon><infon key="name_2">surname:Murray;given-names:MM</infon><infon key="name_1">surname:Gorski;given-names:JJ</infon><infon key="name_0">surname:Hosey;given-names:AM</infon><infon key="fpage">1683</infon><infon key="pub-id_pmid">18000219</infon><infon key="year">2007</infon><infon key="source">J Natl Cancer Inst</infon><infon key="type">ref</infon><infon key="volume">99</infon><infon key="section_type">REF</infon><infon key="lpage">1694</infon><infon key="name_4">surname:Chung;given-names:WY</infon><offset>16418</offset><text>Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer</text><annotation id="24103"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="16476" length="5" /><text>BRCA1</text></annotation><annotation id="24104"><infon key="identifier">2099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47906</infon><location offset="16438" length="17" /><text>estrogen receptor</text></annotation></passage><passage><infon key="name_3">surname:Reddy;given-names:ES</infon><infon key="name_2">surname:Reddy;given-names:A</infon><infon key="name_1">surname:Watkins;given-names:T</infon><infon key="name_0">surname:Xu;given-names:J</infon><infon key="fpage">939</infon><infon key="pub-id_pmid">19287951</infon><infon key="year">2009</infon><infon key="source">Int J Oncol</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="section_type">REF</infon><infon key="lpage">949</infon><infon key="name_4">surname:Rao;given-names:VN</infon><offset>16503</offset><text>A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells</text><annotation id="24105"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="16529" length="5" /><text>BRCA1</text></annotation><annotation id="24106"><infon key="identifier">7329</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5574</infon><location offset="16631" length="4" /><text>Ubc9</text></annotation></passage><passage><infon key="name_3">surname:Begum;given-names:N</infon><infon key="name_2">surname:Aysola;given-names:K</infon><infon key="name_1">surname:Xu;given-names:J</infon><infon key="name_0">surname:Qin;given-names:Y</infon><infon key="fpage">3355</infon><infon key="pub-id_pmid">21344391</infon><infon key="year">2011</infon><infon key="source">J Cell Physiol</infon><infon key="type">ref</infon><infon key="volume">226</infon><infon key="section_type">REF</infon><infon key="lpage">3367</infon><infon key="name_4">surname:Reddy;given-names:V</infon><offset>16719</offset><text>Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins</text><annotation id="24107"><infon key="identifier">672</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5276</infon><location offset="16780" length="5" /><text>BRCA1</text></annotation><annotation id="24108"><infon key="identifier">7329</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5574</infon><location offset="16719" length="4" /><text>Ubc9</text></annotation></passage><relation id="R1"><infon key="score">0.7041</infon><infon key="role1">Disease|MESH:D064726</infon><infon key="role2">Gene|5241</infon><infon key="type">Negative_Correlation</infon></relation><relation id="R2"><infon key="score">0.9333</infon><infon key="role1">Disease|MESH:D064726</infon><infon key="role2">Gene|2099</infon><infon key="type">Negative_Correlation</infon></relation><relation id="R3"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D064726</infon><infon key="role2">Gene|672</infon><infon key="type">Association</infon></relation></document>
</collection>